LY2439821

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Rheumatoid Arthritis

Phase 1

A Study of LY2439821 in Rheumatoid Arthritis

CompletedNCT01236118

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2010-12-31End: 2013-01-31Updated: 2016-05-26

A Study in Rheumatoid Arthritis

CompletedNCT01253265

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2010-05-31End: 2011-12-31Updated: 2016-05-26

Phase 2

A Study in Patients With Rheumatoid Arthritis

CompletedNCT00966875

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2009-08-31End: 2012-06-30Updated: 2016-05-26

Related Papers

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

The Journal of Rheumatology2015-12-1533 citations